Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy, Bortezomib, and Sitagliptin for GvHD Prevention in Allogeneic HSCT
NCT07675174Phase 2Not yet recruiting
- Sponsor
- Northwell Health
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of sitagliptin, bortezomib, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Northwell Health. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sitagliptinbortezomibcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07675174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675174.